Vince Emery is Senior Vice-President (Global Strategy and Engagement) and Professor of Translational Virology at the University of Surrey and holds an Honorary Professorship of Virology at University College London (UCL). He is also Chair of the Middle East and North Africa Community of Practice for the International Unit of UUK.

Vince started his scientific career as a biochemist but has been a virologist for the last 31 years. His current research aims to provide a holistic approach to understanding viral infections in immunocompromised hosts such as HIV-infected patients and transplant recipients.

His particular interests have been focused on cytomegalovirus in solid organ and stem cell transplant recipients by combining viral replication measures with assessment of the immune response and mathematical biology to improve patient management. During his career he has obtained in excess of £25 million of grant money from Government agencies in the UK and USA, charitable organisations, and the private sector and has a H-index of 61 and his work has been cited over 10,500 times.

Vince is a Deputy Director of a UCL led consortium called i-sense (www.i-sense.org.uk ) which is funded by a £11 million grant from the EPSRC to develop novel sensing methods for infectious diseases and was previously part of a team of researchers which included UCL and the SME OJ-Bio developing novel point-of-care HIV diagnostics.

Vince has published in excess of 225 research articles, reviews, and books including a “Pocket Guide to Cytomegalovirus” and “A Patient’s Guide to Cytomegalovirus” published in 2009, and “A spotlight on Cytomegalovirus Infection and Disease” as part of the Lectures in Transplantation series, published in 2010. In addition, Vince is also a named inventor on 5 patents in the area of biotechnology and molecular diagnostics.

Marashi SM, Raeiszadeh M, Enright V, Tahami F, Workman S, Chee R, Webster AD, Milne RS, Emery VC. (2012) 'Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency.'. J Allergy Clin Immunol, United States: 129 (5), pp. 1349-1356.e3. doi: 10.1016/j.jaci.2012.02.011 Marashi SM, Raeiszadeh M, Workman S, Rahbar A, Soderberg-Naucler C, Klenerman P, Chee R, Webster AD, Milne RS, Emery VC. (2011) 'Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus.'. J Allergy Clin Immunol, United States: 127 (6), pp. 1385-93.e4. doi: 10.1016/j.jaci.2011.04.001 Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. (2011) 'Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.'. Lancet, England: 377 (9773), pp. 1256-1263. doi: 10.1016/S0140-6736(11)60136-0 Shannon-Lowe CD, Emery VC. (2010) 'The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein.'. Herpesviridae, England: 1 (1) doi: 10.1186/2042-4280-1-4